Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan 24;29(2):490-496.
doi: 10.3390/curroncol29020044.

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Cheng Zu  1   2   3   4 , Yufeng Xu  5 , Yiyun Wang  1   2   3   4 , Mingming Zhang  1   2   3   4 , Houli Zhao  1   2   3   4 , Xiaoyun Fang  5 , He Huang  1   2   3   4 , Yongxian Hu  1   2   3   4
Affiliations
Case Reports

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Cheng Zu et al. Curr Oncol. .

Abstract

Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients. In multiple myeloma (MM) patients, CMV retinitis has been reported in the post-transplant setting, with an incidence lower than 0.2%, and in patients receiving lenalidomide. Here, we describe the first case of CMV retinitis in myeloma patients following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (BCMA CAR-T) cell therapy. In addition to CMV, the patient developed multiple infections including a mouth ulcer, pneumonia, and fungal enteritis. While the complete remission (CR) status of MM was maintained, he regained a visual acuity of 20/1000 after appropriate ophthalmologic treatment. This single case illustrates the potential of BCMA CAR-T therapy to induce profound humoral immunosuppression, and demonstrates an imperative need for an established standard of monitoring and prophylaxis of post-CAR-T infections.

Keywords: chimeric antigen receptor T cells; cytomegalovirus infection; multiple myeloma; retinal detachment; retinitis.

PubMed Disclaimer

Conflict of interest statement

All of the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
A timeline of the case. (A) Post-CAR-T flow cytometry of bone marrow sample and PET-CT confirmed the complete remission of multiple myeloma. (B) Anterior segment examination and fundoscopy at the diagnosis of CMV retinitis. (C) Ultrasonography of the right eye confirmed retinal detachment. (D) Fundoscopy after the removal of silicone oil tamponade, showing recovery from CMV retinitis and retinal detachment.
See this image and copyright information in PMC

References

    1. Boeckh M. Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future. Hematology. 2011;2011:305–309. doi: 10.1182/asheducation-2011.1.305. - DOI - PubMed
    1. Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 1992;5:1069–1074. doi: 10.1097/00006982-199313030-00016. - DOI - PubMed
    1. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;42:S70–S72. doi: 10.1038/bmt.2008.120. - DOI - PubMed
    1. Teh B.W., Khot A.S., Harrison S.J., Prince H.M., Slavin M.A. A messenger at the door: Cytomegalovirus retinitis in myeloma patients with progressive disease. Transpl. Infect. Dis. Off. J. Transplant. Soc. 2013;15:134–138. doi: 10.1111/tid.12106. - DOI - PubMed
    1. Dhakal B., Hari P.N., Usmani S.Z., Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: Promise and challenges. Bone Marrow Transplant. 2021;56:9–19. doi: 10.1038/s41409-020-01023-w. - DOI - PubMed

Publication types

MeSH terms

Substances